JournalsHub
.online
Find My Journal
KB

Kate F. Byth

Ifm Therapeutics (United States) US

ORCID 0000-0002-8974-8511
61
Publications
1,594
Citations
20
H-Index
21
i10-Index
12.0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis OA
Robert W. Wilkinson, Rajesh Odedra, Simon P. Heaton, Stephen R. Wedge, Nicholas Keen +14 more
Clinical Cancer Research 2007
356
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity OA
Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft, Filippos Michopoulos, Nichola Whalley +10 more
Oncotarget 2017
151
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6 OA
William McCoull, Tony Cheung, Erica Anderson, Peter Barton, Jonathan Burgess +32 more
ACS Chemical Biology 2018
136
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Kate F. Byth, Andrew P. Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor +9 more
Molecular Cancer Therapeutics 2009
122
Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors OA
Kate F. Byth, Janet D. Culshaw, Stephen Green, Sandra Oakes, Andrew P. Thomas
Bioorganic & Medicinal Chemistry Letters 2004
113

Publications

61 total

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth, Justin Cidado, Ammar Adam et al. - Clinical Cancer Research, 2020
Cited by 68 OpenAlex

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6 PDF

William McCoull, Tony Cheung, Erica Anderson, Peter Barton, Jonathan Burgess et al. - ACS Chemical Biology, 2018
Cited by 136 OpenAlex

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity PDF

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft, Filippos Michopoulos, Nichola Whalley et al. - Oncotarget, 2017
Cited by 151 OpenAlex

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors PDF

William McCoull, Roman Abrams, Erica Anderson, Kevin Blades, Peter Barton et al. - Journal of Medicinal Chemistry, 2017
Cited by 78 OpenAlex

Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum PDF

Danielle Greenawalt, Winnie S. Liang, Sakina Saif, Justin Johnson, Petar V. Todorov et al. - Oncotarget, 2017
Cited by 33 OpenAlex

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma PDF

Scott A. Ezell, Suping Wang, Teeru Bihani, Zhongwu Lai, Shaun Grosskurth et al. - Oncotarget, 2016
Cited by 32 OpenAlex

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma PDF

Scott A. Ezell, Michele Mayo, Teeru Bihani, Suprawee Tepsuporn, Suping Wang et al. - Oncotarget, 2014
Cited by 54 OpenAlex

Essential role of TAK1 in regulating mantle cell lymphoma survival PDF

Daniela Buglio, Sangeetha Palakurthi, Kate F. Byth, Francisco Vega, Dorin Toader et al. - Blood, 2012
Cited by 57 OpenAlex

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew P. Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor et al. - Molecular Cancer Therapeutics, 2009
Cited by 122 OpenAlex

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors PDF

Clifford D. Jones, David Andrews, Andrew Barker, Kevin Blades, Kate F. Byth et al. - Bioorganic & Medicinal Chemistry Letters, 2008
Cited by 39 OpenAlex

Research Topics

Cytokine Signaling Pathways and Interactions (26) Mathematical Biology Tumor Growth (22) Cancer-related Molecular Pathways (10) Chronic Myeloid Leukemia Treatments (9) Microtubule and mitosis dynamics (8)

Frequent Co-Authors

ST
Stephen Green
4 joint publications
AN
Andrew P. Thomas
4 joint publications
SA
Sandra Oakes
4 joint publications
WI
William McCoull
3 joint publications
MI
Michael Zinda
3 joint publications
ST
Stephen E. Fawell
3 joint publications

Affiliations

AstraZeneca (United Kingdom)
GB 2014 - 2004
Ifm Therapeutics (United States)
US 2025 - 2021
AstraZeneca (Brazil)
BR 2023 - 2020
AstraZeneca (United States)
US 2023 - 2007

External Profiles

OpenAlex Profile Search Semantic Scholar ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now